Brain Infection Herpes Test Gets FDA Safety Nod
Published Date: 6/26/2025
Rule
Summary
The FDA is officially putting the herpes simplex virus test for brain infections into a special safety category called Class II. This means the test will have clear rules to keep it safe and effective, helping patients get better access to this important tool. The change aims to make things smoother for companies without costing extra time or money.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Test Classified as Class II Device
The FDA has officially classified the herpes simplex virus nucleic acid-based assay for central nervous system infections as a Class II device with special controls. This means the FDA says there are special rules to help ensure the test is safe and effective.
Rule Aims to Improve Patient Access
The FDA says this Class II classification will enhance patients' access to beneficial innovative devices by reducing regulatory burdens. That means the FDA expects the change to help get this kind of herpes simplex virus test to patients more easily.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20063, Request for Nominations for Voting Members of Food and Drug Administration Advisory Committees
The FDA is looking for smart, qualified people to join its advisory committees and help make important decisions about food and drugs. If you have the right skills, you can apply anytime, but get your nomination in by November 30, 2026, for the best chance at current openings. This is a great chance to influence public health without any cost to you!
Previous / Next Documents
Previous: 2025-11793, Medical Devices; Hematology and Pathology Devices; Classification of the Fluorescence In Situ Hybridization-Based Detection of Chromosomal Abnormalities From Patients With Hematologic Malignancies
The FDA is officially putting a special kind of test that spots chromosome problems in blood cancer patients into a safer, more controlled category called Class II. This change helps make sure the test works well and is safe, while also making it easier for new and helpful devices to reach patients faster. Labs and device makers should get ready for these new rules, which aim to speed up access without extra costs.
Next: 2025-11796, Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Muscular Dystrophy Newborn Screening Test
The FDA is officially putting the muscular dystrophy newborn screening test into a special safety category called Class II. This means the test will have clear rules to keep it safe and effective, helping babies get diagnosed early. This change makes it easier for new, helpful tests to reach patients faster without extra red tape.